Stockscreener 앱 받기
19.13
3.13%
0.58
시간 외 거래:
19.13
Kailera Therapeutics Inc 주식(KLRA)의 최신 뉴스
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic? - Yahoo! Finance Canada
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
Parabilis sets biotech IPO record with $670M raise - MSN
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Parabilis Is Now the Largest VC-Backed Biotech IPO - Morningstar
Parabilis now the largest VC-backed biotech IPO - Yahoo Finance
Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record - Citeline News & Insights
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Parabilis takes top spot, pricing largest biopharma IPO at $670M - BioWorld News
Parabilis Medicines raises $670M in upsized IPO - Axios
Parabilis targets $745 million in record-setting biotech IPO - The Pharma Letter
Cancer biotech Parabilis books record IPO, raising $670m - pharmaphorum
3 potential takeover targets in obesity - Pharma Voice
Kailera Therapeutics Launches Commercial Strategy Following $625 Million IPO - geneonline.com
New obesity drug ribupatide shows up to 12.1% weight loss in Phase 2 trial, advancing to global Phase 3. - Pluang
Hengrui Pharma and Kailera Therapeutics Announce Promising Clinical Results for Ribupatide in Obesity Treatment at ADA 2026 - Quiver Quantitative
Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks - TradingView
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 - GlobeNewswire
KLRA: Ribupatide franchise advances with pivotal trials, strong efficacy, and robust financial backing - TradingView
KLRA: Advancing a comprehensive obesity pipeline with pivotal data and strong financial backing - TradingView
Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat
Is Kailera Therapeutics a buy after its sizzling IPO? - MSN
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Post-IPO, Kailera looks beyond obesity to MASH - BioCentury
Kailera’s three-pronged obesity shot shows promise in early trial - BioPharma Dive
Kailera Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Risk Factors, and Management Analysis - Minichart
Kailera Therapeutics Reports Q1 2026 Financial Results, Advances Multiple Clinical-Stage Obesity Programs, and Raises $718.8M in IPO - Minichart
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KLRA SWOT Analysis: Financial Struggles and Growth Potential Rev - GuruFocus
KLRA: Ribupatide injection achieved 23.6% mean weight loss in Phase 2, leading a robust obesity pipeline - TradingView
Kailera Therapeutics, Inc. 1Q 2026: Net loss $78.9M, EPS $(3,650.00) — 10-Q Summary - TradingView
Kailera Therapeutics (Nasdaq: KLRA) boosts obesity R&D with IPO-funded runway - Stock Titan
Kailera Therapeut reports Q1 2026 net loss of $78.9M, $581.9M cash on hand - TradingView
KLRA: Advanced obesity pipeline, strong clinical data, and $718.8M IPO extend funding to mid-2028 - TradingView
Cash-strong Kailera (NASDAQ: KLRA) widens Q1 loss while accelerating obesity pipeline - Stock Titan
Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates - Moomoo
KLRAKailera Therapeutics Inc Stock Price and Quote - Finviz
Meet the new IPO trying to take on Eli Lilly and Novo Nordisk in obesity - MSN
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
This weight-loss drug challenger could follow Eli Lilly's playbook: Analyst - MSN
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? - AOL.com
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
Kailera Therapeutics IPO: Competing with Eli Lilly and Novo Nordisk in GLP-1 Weight LossNews and Statistics - IndexBox
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
How AI is Transforming Health Literacy and Engagement - William Blair
RTW Bio NAV Rises 7.0% In April As Biotech IPO And M&A Activity Accelerates - DirectorsTalk Interviews
Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
2.60%
0.94%
자본화:
|
볼륨(24시간):